Scott Dunseth Myers
Scott Dunseth Myers's purchase track record
How the stock did after each of Scott Dunseth Myers's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/30/2025 | ZNTL | $29K | -2.8% | +7.8% | +23.7% |
| 4/12/2023 | VRDN | $101K | -19.7% | -46.9% | +7.0% |
| 3/13/2023 | VRDN | $160K | -11.6% | -38.1% | +16.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roche wins FDA approval for home thyroid eye disease therapy. Roche received FDA approval for the first at-home treatment for thyroid eye disease, a development relevant to Viridian Therapeutics as it operates in the same therapeutic space. While Viridian's stock is currently trading near its 52-week low, analysts maintain an average price target significantly higher than the current market price. The news highlights competitive dynamics in the thyroid eye disease market that investors may be monitoring.
Transaction History
| ZNTL | ▲ Buy | Grant | 57,100 | $0 | 6/16/2026 | View on chart |
| ZNTL | ▲ Buy | Grant | 57,603 | $0 | 6/17/2025 | View on chart |
| ZNTL | ▲ Buy | Open Market | 21,000 | $29K | 4/30/2025 | View on chart |
| ZNTL | ▲ Buy | Grant | 260,192 | $0 | 11/13/2024 | View on chart |
| VRDN | ▲ Buy | Open Market | 4,000 | $101K | 4/12/2023 | View on chart |
| VRDN | ▲ Buy | Open Market | 5,500 | $160K | 3/13/2023 | View on chart |
| VRDN | ▲ Buy | Grant | 250,000 | $0 | 2/6/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.